Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China
第一作者机构：[10]The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Shijiazhuang, China
推荐引用方式(GB/T 7714)：
Zhou Ye.Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41:803-803.
APA：
Zhou, Ye.(2023).Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China.JOURNAL OF CLINICAL ONCOLOGY,41,
MLA：
Zhou, Ye."Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China".JOURNAL OF CLINICAL ONCOLOGY 41.(2023):803-803
医学